• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cancer Research and Treatment >Gene Expression of OCT4 and NANOG Correlated with Advanced Stage and Worse Survival in Breast Cancer Patients
【24h】

Gene Expression of OCT4 and NANOG Correlated with Advanced Stage and Worse Survival in Breast Cancer Patients

机译：乳腺癌患者OCT4和NANOG的基因表达与晚期和不良生存相关

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The present study aimed to show the correlation between expression of cancer stem cell markers (OCT4 and NANOG) with both clinicopathological features and survival of breast cancer (BC) patients. Methods: The gene expressions of OCT4 and NANOG were quantified using real time polymerase chain reaction, clinicopathological data have been collected from patients' data records and patients were followed-up with a median duration of 110 months. Results: OCT4 (p<0.001), and NANOG (p<0.001) expressions were upregulated in BC tissues compared to adjacent normal tissues. OCT4 and NANOG were associated with poor histological grade (p=0.029, 0.025) and advanced clinical stage (p=0.001, 0.042 respectively). OCT4 alone showed a significant association with lymph nodes involvement (p=0.006), metastasis (p=0.024) and was significantly correlated to patients' age (p=0.009). NANOG also showed a significant positive correlation with ERα and PR receptors expression (p=0.004 and 0.005 respectively). Kaplan–Meier curves disclosed that NANOG (p=0.028, 0.050) positive expression was associated with worse DFS and OS, while OCT4 (p=0.200, 0.205) was correlated with poor DFS and OS but not significant statistically. Univariate analysis using Cox proportional hazards regression model analysis showed that OCT4 (p?=?0.002), NANOG (p?=?0.021), and ERα status (p?=?0.004) had significant predictive values for poor DFS. However, the multivariate analysis did not show that any of them can be used as independent prognostic markers for DSF. Conclusions: From these findings, it may be concluded that the upregulated expressions of OCT4 and NANOG were associated with worse clinical outcome and could be used as predictive markers for poor DFS in BC patients.
机译：本研究旨在显示癌症干细胞标志物（OCT4和NANOG）的表达与乳腺癌（BC）患者的临床病理特征和生存率之间的相关性。方法：采用实时聚合酶链反应对OCT4和NANOG的基因表达进行定量，从患者的病历中收集临床病理资料，并进行随访，中位时间为110个月。结果：与邻近的正常组织相比，BC组织中的OCT4（p <0.001）和NANOG（p <0.001）表达上调。 OCT4和NANOG与较差的组织学分级（p = 0.029，0.025）和晚期临床阶段（p = 0.001，0.042）有关。单独的OCT4与淋巴结受累（p = 0.006），转移（p = 0.024）显着相关，并且与患者年龄显着相关（p = 0.009）。 NANOG还显示与ERα和PR受体表达显着正相关（分别为p = 0.004和0.005）。 Kaplan–Meier曲线显示，NANOG（p = 0.028，0.050）阳性表达与较差的DFS和OS相关，而OCT4（p = 0.200，0.205）与较差的DFS和OS相关，但在统计学上不显着。使用Cox比例风险回归模型分析的单变量分析表明，OCT4（p？=？0.002），NANOG（p？=？0.021）和ERα状态（p？=？0.004）对不良DFS具有重要的预测价值。但是，多变量分析并未显示它们中的任何一个都可以用作DSF的独立预后指标。结论：从这些发现，可以得出结论，OCT4和NANOG的表达上调与较差的临床预后有关，并可作为BC患者DFS不良的预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号